Stefania Oliva

Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group

Antonio Palumbo, Hervé Avet‐Loiseau, Stefania Oliva et al. · Journal of Clinical Oncology · 2015 · 2.1K citations · Full text

Autologous haematopoietic stem-cell transplantation versus bortezomib–melphalan–prednisone, with or without bortezomib–lenalidomide–dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study

Michèle Cavo, Francesca Gay, Meral Beksaç et al. · The Lancet Haematology · 2020 · 377 citations · Full text

Hematological Malignancy, Transplantation, Marrow Transplantation +9

Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial

Francesca Gay, Stefania Oliva, Maria Teresa Petrucci et al. · The Lancet Oncology · 2015 · 312 citations · Full text

Hematological Malignancy, Transplantation, Marrow Transplantation +12

Clinical features associated with COVID-19 outcome in multiple myeloma: first results from the International Myeloma Society data set

Ajai Chari, Mehmet Samur, Joaquín Martínez‐López et al. · Blood · 2020 · 181 citations · Full text

Carfilzomib, cyclophosphamide, and dexamethasone in patients with newly diagnosed multiple myeloma: a multicenter, phase 2 study

Sara Bringhen, Maria Teresa Petrucci, Alessandra Larocca et al. · Blood · 2014 · 153 citations